Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia

Journal of the National Cancer Institute

Volumn 103, Issue 11, 2011, Pages 893-905

  Hu, Shuiying ^a   Niu, Hongmei ^a   Inaba, Hiroto ^b   Orwick, Shelley ^a   Rose, Charles ^a   Panetta, John C ^a   Yang, Shengping ^b   Pounds, Stanley ^b   Fan, Yiping ^b   Calabrese, Christopher ^a   Rehg, Jerold E ^b   Campana, Dario ^b   Rubnitz, Jeffrey E ^b   Baker, Sharyn D ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b Department of Oncology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER C10; ABC TRANSPORTER C11; CYTARABINE; DRUG METABOLITE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; SORAFENIB; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC THERAPY; ANTILEUKEMIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CELL PROLIFERATION; CELL VIABILITY; CHILD; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EXPOSURE; DRUG POTENTIATION; DRUG TOLERABILITY; ENZYME INDUCTION; ENZYME PHOSPHORYLATION; FEMALE; GENE EXPRESSION REGULATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL LINE; MONOTHERAPY; MOUSE; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; STEADY STATE; TANDEM MASS SPECTROMETRY;

EID: 79958789936     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr107     Document Type: Article

References (49)

1. Scholl C, Gilliland DG, Frohling S. Deregulation of signaling pathways in acute myeloid leukemia. Semin Oncol. 2008;35(4):336-345.
2. Park S, Chapuis N, Tamburini J, et al. Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia. Haematologica. 2010;95(5):819-828.
3. Platanias LC. Map kinase signaling pathways and hematologic malignancies. Blood. 2003;101(12):4667-4679. (Pubitemid 36857719)
4. Min YH, Eom JI, Cheong JW, et al. Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: its significance as a prognostic variable. Leukemia. 2003;17(5):995-997. (Pubitemid 36626336)
5. Milella M, Kornblau SM, Estrov Z, et al. Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J Clin Invest. 2001;108(6):851-859. (Pubitemid 32880294)
6. Grandage VL, Gale RE, Linch DC, et al. PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways. Leukemia. 2005;19(4):586-594. (Pubitemid 40521164)
7. Kornblau SM, Womble M, Qiu YH, et al. Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood. 2006;108(7):2358-2365. (Pubitemid 44497520)
8. Kornblau SM, Tibes R, Qiu YH, et al. Functional proteomic profiling of AML predicts response and survival. Blood. 2009;113(1):154-164.
9. Gallay N, Dos Santos C, Cuzin L, et al. The level of AKT phosphorylation on threonine 308 but not on serine 473 is associated with high-risk cytogenetics and predicts poor overall survival in acute myeloid leukaemia. Leukemia. 2009;23(6):1029-1038.
10. Fabian MA, Biggs WH III, Treiber DK, et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol. 2005;23(3):329-336. (Pubitemid 41094421)
11. Mori S, Cortes J, Kantarjian H, et al. Potential role of sorafenib in the treatment of acute myeloid leukemia. Leuk Lymphoma. 2008;49(12):2246-2255.
12. Auclair D, Miller D, Yatsula V, et al. Antitumor activity of sorafenib in FLT3-driven leukemic cells. Leukemia. 2007;21(3):439-445.
13. Zhang W, Konopleva M, Ruvolo VR, et al. Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. Leukemia. 2008;22(4):808-818. (Pubitemid 351552630)
14. Hu S, Niu H, Minkin P, et al. Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia. Mol Cancer Ther. 2008;7(5):1110-1120.
15. Zhang W, Konopleva M, Shi YX, et al. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. J Natl Cancer Inst. 2008;100(3):184-198. (Pubitemid 351480557)
16. Pratz KW, Cho E, Levis MJ, et al. A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias. Leukemia. 2010;24(8):1437-1444.
17. Crump M, Hedley D, Kamel-Reid S, et al. A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study. Leuk Lymphoma. 2010;51(2):252-260.
18. Dent P, Grant S. Pharmacologic interruption of the mitogen-activated extracellular-regulated kinase/mitogen-activated protein kinase signal transduction pathway: potential role in promoting cytotoxic drug action. Clin Cancer Res. 2001;7(4):775-783. (Pubitemid 32708709)
19. Abbott BL, Colapietro AM, Barnes Y, et al. Low levels of ABCG2 expression in adult AML blast samples. Blood. 2002;100(13):4594-4601. (Pubitemid 35429703)
20. Rubnitz JE, Inaba H, Dahl G, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol. 2010;11(6):543-52.
21. Levis M, Pham R, Smith BD, et al. In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects. Blood. 2004;104(4):1145-1150. (Pubitemid 39038036)
22. Greco WR, Bravo G, Parsons JC. The search for synergy: a critical review from a response surface perspective. Pharmacol Rev. 1995;47(2):331-385.
23. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul. 1984;22:27-55.
24. Strumberg D, Clark JW, Awada A, et al. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist. 2007;12(4):426-437. (Pubitemid 46698720)
25. Ozkaynak MF, Avramis VI, Carcich S, et al. Pharmacology of cytarabine given as a continuous infusion followed by mitoxantrone with and without amsacrine/etoposide as reinduction chemotherapy for relapsed or refractory pediatric acute myeloid leukemia. Med Pediatr Oncol. 1998;31(6):475-482. (Pubitemid 28535914)
26. Zhao M, Rudek MA, He P, et al. A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;846(1-2):1-7. (Pubitemid 46149480)
27. Hing JP, Woolfrey SG, Greenslade D, et al. Is mixed effects modeling or naive pooled data analysis preferred for the interpretation of single sample per subject toxicokinetic data? J Pharmacokinet Pharmacodyn. 2001;28(2):193-210.
28. Fujisaki H, Kakuda H, Shimasaki N, et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer research. 2009;69(9):4010-4017.
29. Meerum Terwogt JM, Beijnen JH, ten Bokkel Huinink WW, et al. Co-administration of cyclosporin enables oral therapy with paclitaxel. Lancet. 1998;352(9124):285. (Pubitemid 28340148)
30. Malingre MM, Terwogt JM, Beijnen JH, et al. Phase I and pharmacokinetic study of oral paclitaxel. J Clin Oncol. 2000;18(12):2468-2475. (Pubitemid 30415834)
31. The R Project for Statistical Computing.http://www.r-project.org/ Accessed April 1, 2011.
32. Harley ER, Paterson AR, Cass CE. Initial rate kinetics of the transport of adenosine and 4-amino-7-(beta-D-ribofuranosyl)pyrrolo[2,3-d]pyrimidine (tubercidin) in cultured cells. Cancer Res. 1982;42(4):1289-1295.
33. Graham KA, Leithoff J, Coe IR, et al. Differential transport of cytosine-containing nucleosides by recombinant human concentrative nucleoside transporter protein hCNT1. Nucleosides Nucleotides Nucleic Acids. 2000;19(1-2):415-434. (Pubitemid 30230051)
34. Boleti H, Coe IR, Baldwin SA, et al. Molecular identification of the equilibrative NBMPR-sensitive (es) nucleoside transporter and demonstration of an equilibrative NBMPR-insensitive (ei) transport activity in human erythroleukemia (K562) cells. Neuropharmacology. 1997;36(9):1167-1179. (Pubitemid 27465605)
35. Wang LM, Woodward CN, White JC, et al. Determination of 3H-labelled cytosine arabinoside and eight metabolites in cell extracts by high-performance liquid chromatography and scintillation spectrometry. J Chromatogr. 1989;491(2):331-340. (Pubitemid 19191177)
36. Parker WB, Shaddix SC, Chang CH, et al. Effects of 2-chloro-9-(2-deoxy-2- fluoro-beta-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5′-triphosphate. Cancer Res. 1991;51(9):2386-2394.
37. http://www.affymetrix.com/partners-programs/programs/developer/stat-sdk/ index.affx-method. Accessed June 1, 2010.
38. Kaplan EL, Meier P. Nonparamteric estimation from incomplete observations. J Amer Stat Assoc. 1958;53:457-481.
39. Kufe D, Spriggs D, Egan EM, et al. Relationships among Ara-CTP pools, formation of (Ara-C)DNA, and cytotoxicity of human leukemic cells. Blood. 1984;64(1):54-58. (Pubitemid 14085726)
40. Estey E, Plunkett W, Gandhi V, et al. Fludarabine and arabinosylcytosine therapy of refractory and relapsed acute myelogenous leukemia. Leuk Lymphoma. 1993;9(4-5):343-350. (Pubitemid 23209513)
41. Hu S, Chen Z, Franke R, et al. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res. 2009;15(19):6062-6069.
42. Hopper-Borge E, Xu X, Shen T, et al. Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogues and epothilone B. Cancer Res. 2009;69(1):178-184.
43. Guo Y, Kotova E, Chen ZS, et al. MRP8, ATP-binding cassette C11 (ABCC11), is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines 2′,3'-dideoxycytidine and 9′-(2'- phosphonylmethoxyethyl)adenine. J Biol Chem. 2003;278(32):29509-29514. (Pubitemid 36962331)
44. Ravandi F, Cortes JE, Jones D, et al. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol. 2010;28(11):1856-1862.
45. Huang M, Wang Y, Mitchell BS, et al. Regulation of equilibrative nucleoside uptake by protein kinase inhibitors. Nucleosides Nucleotides Nucleic Acids. 2004;23(8-9):1445-1450. (Pubitemid 39625940)
46. Huang M, Wang Y, Cogut SB, et al. Inhibition of nucleoside transport by protein kinase inhibitors. J Pharmacol Exp Ther. 2003;304(2):753-760. (Pubitemid 36152354)
47. Borst P, de Wolf C, Van De Wetering K. Multidrug resistance-associated proteins 3, 4, and 5. Pflugers Arch - Eur J Physiol. 2007;453(5):661-673. (Pubitemid 46192537)
48. Kruh GD, Guo Y, Hopper-Borge E, et al. ABCC10, ABCC11, and ABCC12. Pflugers Arch. 2007;453(5):675-684.
49. Nishioka C, Ikezoe T, Yang J, et al. Inhibition of MEK signaling enhances the ability of cytarabine to induce growth arrest and apoptosis of acute myelogenous leukemia cells. Apoptosis. 2009;14(9):1108-1120.